Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,552 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings Classification · 82% confidence The document is a formal disclosure under Regulation 30 of SEBI LODR filed with Indian stock exchanges, notifying an acceptance order issued by a tax authority and stating no material impact. It does not contain financial statements or constitute an annual/interim report, nor does it announce dividends, board changes, or capital activities. It is a regulatory compliance announcement. Therefore, it falls under the ‘Regulatory Filings’ category (RNS).
2026-05-27 English
Please find enclosed intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Regulatory Filings Classification · 88% confidence The document is a formal disclosure under SEBI (LODR) Regulation 30 to BSE and NSE, reporting a tax authority’s acceptance order. It contains no financial statements or operational results and is not an AGM, earnings release, or detailed report. This is a general regulatory announcement of a corporate/legal matter, falling under the Regulatory Filings category (RNS).
2026-05-27 English
Copy of Newspaper Publication
Regulatory Filings Classification · 80% confidence The document is a formal letter from Sanofi India Limited to the BSE and NSE secretaries, submitted under SEBI (LODR) Regulation 30. It encloses copies of a newspaper publication regarding a “Special Window for Transfer and Dematerialisation of physical shares.” This is a routine regulatory announcement/disclosure to the stock exchanges (a miscellaneous regulatory filing) rather than an actual financial report or meeting material. Therefore, it falls under Regulatory Filings (RNS).
2026-05-20 English
Please find enclosed copies of the Newspaper publication regarding the information on special window for transfer and dematerialisation of physical shares.
Regulatory Filings Classification · 85% confidence The document is an exchange filing under SEBI (Listing Obligations and Disclosure Requirements) Regulation 30 notifying the publication of a newspaper notice about the special window for transfer and dematerialisation of physical shares. It contains no financial statements, no dividend or capital change details, and is not a transcript, management report, or formal report itself. This is a miscellaneous regulatory announcement under continuous disclosure requirements, fitting the fallback category ‘Regulatory Filings (RNS)’.
2026-05-20 English
Press Release
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Mr. Rahul Bhatnagar as the Chairman of the Board of Directors of Sanofi India Limited. It includes details about the outgoing chairman and other board members, as well as background information about the company. There are no financial statements, audit information, or detailed management discussion. The document is clearly about a change in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is 4193 characters, which is consistent with a typical announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2026-04-30 English
Please find enclosed Press Release dated 30th April 2026
Board/Management Information Classification · 94% confidence The document is a formal press release under Regulation 30 of SEBI LODR announcing the appointment of Mr. Rahul Bhatnagar as Chairman of the Board, and noting departures of existing independent directors. It clearly pertains to changes in the company’s board of directors, fitting the Board/Management Information category.
2026-04-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.